Kelso Pharma acquires UK pharma business, Alturix

Kelso Pharma, the British specialty pharma business backed by Apposite Capital, today announced the acquisition of the UK pharma business, Alturix Holdings Limited. Financial terms were not disclosed.

The company noted that the transaction marks a significant step towards Kelso’s vision of building a specialty pharma business of scale in the UK and ultimately across Europe.  The acquisition will be complementary, with Kelso Pharma and Alturix sharing a common philosophy of supplying branded specialty medicines that provide patient benefits and a reduced cost burden to the National Health Service (NHS).

Alturix has seven branded medicines in the UK market today, driving double digit top-line revenue growth. These are in the therapeutic areas of central nervous system, respiratory disease and endocrinology.